Pantoprazole (sodium)

Pantoprazole sodium (BY10232 sodium) is an orally active and potent proton pump inhibitor (PPI)^[1]. Pantoprazole sodium, a substituted benzimidazole, is a potent H⁺/K⁺-ATPase inhibitor with an IC₅₀ of 6.8 μM. Pantoprazole sodium improves pH stability and has anti-secretory, anti-ulcer activities. Pantoprazole sodium significantly increased tumor growth delay combined with Doxorubicin (HY-15142)^[3][4]. IC50 & Target: proton pump In Vitro: Pantoprazole sodium (BY1023 sodium; 1-10000 μM) leads to concentration-dependent increases in endosomal pH in EMT-6 and MCF7 cells^[1].
Pantoprazole sodium can block exosome release. Pantoprazole sodium inhibits the activity of V-H⁺-ATPase and impaires the ability of tumour cells (melanomas, adenocarcinomas, and lymphoma cell lines) to acidify the extracellular medium^[2] In Vivo: Pantoprazole sodium (BY1023 sodium; 200 mg/kg; IP; once a week for 3 weeks) significantly increases tumor growth delay of MCF-7 xenografts combined with Doxorubicin^[1].
Pantoprazole sodium (0.3-3 mg/kg, p.o.) dose-dependently decreases both basal acid secretion in pylorus-ligated rats and the stimulated acid secretion induced by mepirizole in acute fistula rats^[4].